Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Another in vivo Car speeds into the clinic
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
GSK makes haste while Daiichi struggles
Mocertatug rezetecan is starting its first western pivotal trials.
Astra enters the pan-KRAS game
A deal with Jacobio is worth $100m up front.
